Titan Pharmaceuticals (TTNP) AI Stock Analysis

• Market Cap: $4.02M
• Dividend Yield: N/A
• Average Volume (3M): 34.06K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.13
• Revenue Growth: -100.00%
• EPS Growth: 28.48%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -5.23
• Shares Outstanding: 914,234
• 10 Day Avg. Volume: 8,577
• 30 Day Avg. Volume: 34,059
• PEG Ratio: 0.11
• Price to Book (P/B): 7.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.28
• Enterprise Value/Market Cap: 1.92
• Enterprise Value/Revenue: 46.56
• Enterprise Value/Gross Profit: -2.58K
• Enterprise Value/Ebitda: -0.36
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 34 Underperform
• Price Target: ―

Titan Pharmaceuticals' stock faces considerable financial performance issues, with declining revenues, negative cash flows, and operational inefficiencies posing significant challenges. Technical analysis indicates a lack of clear momentum, while valuation metrics are unattractive due to negative earnings. The lack of recent earnings call data or relevant corporate events leaves these negative factors largely unchecked, resulting in a low overall stock score.

Titan Pharmaceuticals Business Overview & Revenue Model

Company Description

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

How the Company Makes Money

Titan Pharmaceuticals generates revenue primarily through the commercialization of its flagship product, Probuphine. The company earns income from product sales, licensing agreements, and royalties. Probuphine, as a treatment for opioid dependence, is sold to healthcare providers and distributed through specialty pharmaceutical distribution channels. Additionally, Titan engages in strategic partnerships and collaborations with other pharmaceutical companies, which can result in upfront payments, milestone payments, and ongoing royalty streams based on product sales.

Titan Pharmaceuticals Financial Statement Overview

Summary

Titan Pharmaceuticals faces significant financial challenges, marked by declining revenues, persistent losses, and negative cash flows. The company benefits from having no debt, but operational inefficiencies and diminishing asset value overshadow this advantage. Reliance on external financing is a risk, and efforts to stabilize revenue and improve profitability are crucial.

Income Statement

Titan Pharmaceuticals demonstrates a consistent decline in revenue over recent years, with the latest year showing no revenue generation. Gross profit margins have deteriorated, and the company continues to report substantial net losses, indicating ongoing challenges in achieving profitability. The negative EBIT and EBITDA margins reflect operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The balance sheet shows a strong equity position with no current debt, resulting in a zero debt-to-equity ratio. However, the significant decline in total assets and stockholders' equity over time raises concerns about long-term financial health. The equity ratio remains relatively high, but the shrinking asset base could pose risks if the trend continues.

Cash Flow

Cash flow analysis indicates negative operating cash flow and free cash flow in recent years, reflecting difficulties in generating cash from operations. Although there has been a slight improvement in free cash flow year-over-year, the company is still heavily reliant on financing activities to cover its cash requirements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	1.00K	60.00K	1.53M	4.84M
Gross Profit	-3.00K	0.00	1.00K	-136.00K	1.33M	4.37M
EBITDA	-4.03M	-4.70M	-7.17M	-10.04M	-9.13M	-7.06M
Net Income	-4.21M	-4.71M	-5.57M	-10.18M	-8.11M	-20.73M
Balance Sheet
Total Assets	2.16M	2.92M	8.09M	4.06M	7.99M	8.09M
Cash, Cash Equivalents and Short-Term Investments	1.95M	2.83M	6.76M	2.94M	6.04M	5.41M
Total Debt	0.00	0.00	565.00K	187.00K	299.00K	809.00K
Total Liabilities	279.00K	483.00K	1.44M	2.69M	2.86M	4.55M
Stockholders Equity	1.88M	2.44M	6.64M	1.36M	5.14M	3.53M
Cash Flow
Free Cash Flow	-4.13M	-3.88M	-7.09M	-8.18M	-7.92M	-17.74M
Operating Cash Flow	-4.13M	-3.88M	-7.09M	-8.18M	-7.90M	-17.20M
Investing Cash Flow	0.00	0.00	732.00K	0.00	-23.00K	-540.00K
Financing Cash Flow	-81.00K	-62.00K	10.00M	4.98M	8.84M	17.93M

Titan Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.40
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TTNP, the sentiment is Positive. The current price of 4.4 is below the 20-day moving average (MA) of 4.44, below the 50-day MA of 4.40, and above the 200-day MA of 4.06, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 49.51 is Neutral, neither overbought nor oversold. The STOCH value of 34.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TTNP.

Titan Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	kr5.46B	12.72	-80.61%	5.07%	37.36%	27.71%
NBY	45 Neutral	$3.66M	―	-235.50%	―	-49.76%	96.81%
INM	44 Neutral	$3.51M	―	-91.71%	―	-11.94%	56.72%
TTNP	34 Underperform	$4.02M	―	-105.70%	―	-100.00%	28.48%
HEPA		$740.90K	―	-288.06%	―	―	―
GLTO	29 Underperform	$4.68M	―	-91.32%	―	―	48.81%
QNRX	25 Underperform	$5.18M	―	-138.80%	―	―	42.26%

Titan Pharmaceuticals Corporate Events

Titan Pharmaceuticals Appoints Chay Weei Jye as CEO

Chay Weei Jye has been appointed as the new CEO, bringing extensive IT leadership experience from roles at Zchwantech, Affin Bank Berhad, and Malaysian Airlines. His strategic expertise in technology solutions and enterprise architecture is expected to drive the company’s growth, making this a significant development for investors watching the company’s trajectory.